Home » Stocks » BXRX

Baudax Bio, Inc. (BXRX)

Stock Price: $1.01 USD -0.06 (-5.61%)
Updated Apr 19, 2021 12:11 PM EDT - Market open
Market Cap 75.05M
Revenue (ttm) 493,000
Net Income (ttm) -76.10M
Shares Out 70.14M
EPS (ttm) -3.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $1.01
Previous Close $1.07
Change ($) -0.06
Change (%) -5.61%
Day's Open 1.04
Day's Range 1.01 - 1.07
Day's Volume 559,150
52-Week Range 0.97 - 4.95

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investors need to pay close attention to Baudax (BXRX) stock based on the movements in the options market lately.

1 week ago - Zacks Investment Research

Annual Meeting to be adjourned solely with respect to Proposal 3 Annual Meeting to be adjourned solely with respect to Proposal 3

1 week ago - GlobeNewsWire

MALVERN, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committe...

2 weeks ago - GlobeNewsWire

Wall Street recommends purchasing shares of Ra Medical Systems Inc (RMED) and Baudax Bio Inc (NASDAQ:BXRX), which sounds quite unexpected since these two equities have shown poor performance over the pr...

Other stocks mentioned: RMED
1 month ago - GuruFocus

MALVERN, Pa., March 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President ...

1 month ago - GlobeNewsWire

Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

1 month ago - GlobeNewsWire

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President ...

1 month ago - GlobeNewsWire

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...

2 months ago - GlobeNewsWire

MALVERN, Pa., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...

2 months ago - GlobeNewsWire

Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.

2 months ago - Zacks Investment Research

MALVERN, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the agreement by an accredited ...

2 months ago - GlobeNewsWire

MALVERN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company'...

4 months ago - GlobeNewsWire

MALVERN, Pa., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced ...

4 months ago - GlobeNewsWire

ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid Analgesics ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety ...

4 months ago - GlobeNewsWire

Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

BXRX has been pummeled since the start of the pandemic dropping from the high $7s to the low $1s. In this article, I review the company developments, both negative and positive, that have transpired dur...

5 months ago - Seeking Alpha

MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it will report third quarte...

5 months ago - GlobeNewsWire

ANJESO ® Launch Underway ; Over 50 Institutions have A dded ANJESO to T heir F ormular ies

5 months ago - GlobeNewsWire

MALVERN, Pa., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee...

6 months ago - GlobeNewsWire

MALVERN, Pa., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the Company’s ...

7 months ago - GlobeNewsWire

These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead. The post 3 Penny Stocks That Have Triple-Digit Upside Potential appeared fir...

Other stocks mentioned: AMRS, LIFE
7 months ago - InvestorPlace

Baudax Bio: Discounted Despite Long-Term Prospects

7 months ago - Seeking Alpha

MALVERN, Pa., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has been awarded a Gro...

7 months ago - GlobeNewsWire

MALVERN, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Arnold Baskies, M.D. and ...

7 months ago - GlobeNewsWire

Baudax Bio's (BXRX) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Commenced Commercial Launch of ANJESO ® in the U.S.

8 months ago - GlobeNewsWire

Effective October 1, 2020, New Code Expected to Expand Reimbursement Effective October 1, 2020, New Code Expected to Expand Reimbursement

8 months ago - GlobeNewsWire

Virtual Presentation Highlights New ANJESO Clinical Results, Including Safety, Reductions in Opioid Use and Time to Bowel Function Recovery Data When Administered Preoperatively Prior to Colorectal Surg...

8 months ago - GlobeNewsWire

MALVERN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has entered into a Pha...

8 months ago - GlobeNewsWire

ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily Dosing ANJESO Is The Only Approved 24-Hour, Intravenous COX-2 Preferential NSAID that Offers Once-Daily D...

10 months ago - GlobeNewsWire

MALVERN, Pa., June 01, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a credit...

10 months ago - GlobeNewsWire

Baudax Bio, Inc. (BXRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

10 months ago - Zacks Investment Research

  ANJESO™ Approved by FDA for the Management of Moderate to Severe Pain; Product Now Available for Ordering and Delivery for Customers

11 months ago - GlobeNewsWire

Virtual Presentation Highlights New ANJESO Health Resource Utilization Data When Administered Preoperatively in Colorectal Surgery as Part of a Multimodal Analgesia Regimen Virtual Presentation Highligh...

11 months ago - GlobeNewsWire

Baudax Bio, Inc. (BXRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

MALVERN, Pa., April 03, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Commit...

1 year ago - GlobeNewsWire

MALVERN, Pa., March 26, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced ...

1 year ago - GlobeNewsWire

MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced ...

1 year ago - GlobeNewsWire

MALVERN, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (“Baudax” or the “Company”) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced ...

1 year ago - GlobeNewsWire

Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™ Strategic Financing to Provide Funding for the Commercial Launch of ANJESO™

1 year ago - GlobeNewsWire

Tiny, Underfollowed Baudax Bio Way Too Cheap After Receiving FDA Drug Approval

1 year ago - Seeking Alpha

Baudax Bio (BXRX) news for Friday surrounding approval from the U.S. Food & Drug Administration has BXRX stock taking off.

1 year ago - InvestorPlace

Baudax Bio is a recent spin-out of Recro Pharma's Acute Care Segment and is already preparing for Ajenso's PDUFA date on February 20th.

1 year ago - Seeking Alpha

PDUFA Goal Date Set for February 20, 2020 PDUFA Goal Date Set for February 20, 2020

1 year ago - GlobeNewsWire

About BXRX

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMBA) that is in phase I clinical trial; BX2000, an ultrashort-acting NMBA, which is in pre-clinical trial; and BX3000, an NMBA reversal agent, which is under pre-clinical trial,... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
BXRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Baudax Bio stock is "Buy." The 12-month stock price forecast is 4.67, which is an increase of 362.38% from the latest price.

Price Target
$4.67
(362.38% upside)
Analyst Consensus: Buy